Minerva Neurosciences Announces Achievement of Primary and Key Secondary Objectives in Phase 2b Clinical Trial of Seltorexant (MIN-202) in Insomnia

June 24, 2019

We're not around right now. But you can send us an email and we'll get back to you, asap.

Start typing and press Enter to search